Spanish guidelines for the management of autosomal dominant polycystic kidney disease

Publications

>

Review

Spanish guidelines for the management of autosomal dominant polycystic kidney disease

Publicated to:Nephrology Dialysis Transplantation. 29 iv95-iv105 - 2014-01-01 29(), DOI: 10.1093/ndt/gfu186

Authors: Ars E, Bernis C, Fraga G, Martínez V, Martins J, Ortiz A, Rodríguez-Pérez JC, Sans L, Torra R, Spanish Working Group on Inherited Kidney Disease

Affiliations

Hosp del Mar, Nephrol Dept, REDinREN, Barcelona, Spain Institut Hospital del Mar d'Investigacions Mediques (IMIM) Hospital del Mar - Author

Hosp Princesa, Nephrol Dept, REDinREN, Madrid, Spain - Author

Hosp Reina Sofia, Dept Nephrol, Murcia, Spain Hospital Universitario Reina Sofia - Author

Hospital de Gran Canaria Dr. Negrin - Author

Hospital del Mar - Author

Hospital Universitario de Getafe - Author

Hospital Universitario de la Princesa - Author

Hospital Universitario Reina Sofía - Author

Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, E-08193 Barcelona, Spain Autonomous University of Barcelona Hospital of Santa Creu i Sant Pau - Author

Univ Autonoma Barcelona, Inst Invest Carlos III, Dept Nephrol, Fundacio Puigvert,IIB St Pau,REDinREN, E-08193 Barcelona, Spain. Autonomous University of Barcelona Fundacio Puigvert - Author

Univ Autonoma Barcelona, Inst Invest Carlos III, Dept Nephrol, Fundacio Puigvert,IIB St Pau,REDinREN, E-08193 Barcelona, Spain Fundacio Puigvert Autonomous University of Barcelona - Author

Univ Autonoma Barcelona, Inst Invest Carlos III, Mol Biol Lab, IIB St Pau,REDinREN,Fundacio Puigvert, E-08193 Barcelona, Spain Autonomous University of Barcelona Fundacio Puigvert - Author

Univ Autonoma Madrid, IIS Fdn Jimenez Diaz, Nephrol Dept, IRSIN,REDinREN, Madrid, Spain Autonomous University of Madrid Fundacion Jimenez Diaz - Author

Univ Europea Madrid, Hosp Univ Getafe, Nephrol Dept, Madrid, Spain European University of Madrid Hospital Universitario de Getafe - Author

Univ Las Palmas Gran Canaria, Hosp Univ Gran Canaria Dr Negrin, Nephrol Dept, Las Palmas Gran Canaria, Spain Universidad de Las Palmas de Gran Canaria - Author

Universidad Autónoma de Madrid - Author

Universitat Autònoma de Barcelona - Author

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent cause of genetic renal disease and accounts for 6-10% of patients on renal replacement therapy (RRT). Very few prospective, randomized trials or clinical studies address the diagnosis and management of this relatively frequent disorder. No clinical guidelines are available to date. This is a consensus statement presenting the recommendations of the Spanish Working Group on Inherited Kidney Diseases, which were agreed to following a literature search and discussions. Levels of evidence found were C and D according to the Centre for Evidence-Based Medicine (University of Oxford). The recommendations relate to, among other topics, the use of imaging and genetic diagnosis, management of hypertension, pain, cyst infections and bleeding, extra-renal involvement including polycystic liver disease and cranial aneurysms, management of chronic kidney disease (CKD) and RRT and management of children with ADPKD. Recommendations on specific ADPKD therapies are not provided since no drug has regulatory approval for this indication.

Keywords

adpkdautosomal dominant polycystic kidney diseaseguidelinesmanagementAdpkdAutosomal dominant polycystic kidney diseaseGuidelinesManagementRecommendations

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Nephrology Dialysis Transplantation due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2014, it was in position 12/78, thus managing to position itself as a Q1 (Primer Cuartil), in the category Urology & Nephrology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 1.9. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

Weighted Average of Normalized Impact by the Scopus agency: 3.01 (source consulted: FECYT Feb 2024)
Field Citation Ratio (FCR) from Dimensions: 11.19 (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-13, the following number of citations:

WoS: 41
Scopus: 49
Europe PMC: 13
Google Scholar: 104
OpenCitations: 52

Indexed in

License and use

Citations

Altmetrics

Analysis of institutional authors

Share